ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors
Business Wire•16/10/2026•11:49 ET
0
Key Highlights
- ➤84% cystectomy-free survival at 36 months among responders
- ➤71% complete response rate in BCG-unresponsive NMIBC with CIS
- ➤Median complete-response duration reached 26.6 months, extending beyond 53 months
- ➤98.2% disease-specific survival at three years
- ➤No Grade 4 or Grade 5 treatment-related adverse events reported
Expert Statements
Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio
“The QUILT-3.032 study represents one of the longest follow-up data sets in BCG-unresponsive NMIBC to date, and the results continue to support the durability of ANKTIVA’s unique mechanism of action in generating sustained immune responses.”
Patrick Soon-Shiong, Founder, Executive Chairman and Global Chief Scientific and Medical Officer of ImmunityBio
“These long-term findings are encouraging, suggesting the potential for prolonged disease control and the possibility of avoiding or delaying radical cystectomy for some patients.”
Richard Adcock, President and CEO of ImmunityBio
“Achieving a durable response and avoiding cystectomy are important treatment goals for patients with BCG-unresponsive NMIBC.”
Richard Adcock, President and CEO of ImmunityBio
“These peer-reviewed results add to the growing body of evidence supporting ANKTIVA plus BCG and highlight its potential to provide sustained disease control and meaningful cystectomy avoidance for patients with limited treatment options. We thank the patients and clinical teams who contributed to this long-term follow-up.”
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA(® )Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors
Peer-reviewed publication reports long-term outcomes from the QUILT-3.032 study supporting durable disease control and bladder preservation
Get started
Create a free account to read the full story.